Nohales Taurines G, Cortadellas Angel R, Arango Toro O, Bielsa Gali O, Gelabert Mas A
Cátedra y Servicio de Urología, Hospital Universitario del Mar, Universidad Autónoma de Barcelona, España.
Arch Esp Urol. 1996 Sep;49(7):689-92.
The high incidence of recurrence in superficial urothelial cancer warrants the use of chemoprophylaxis; however, the results achieved to date have been unsatisfactory. The present study investigated the possibility of reducing the incidence of recurrence of superficial urothelial cancer post-TUR and disease progression.
METHODS/RESULTS: 99 patients were treated with monthly instillations of mitomycin-C and BCG alternately for one year, which commenced three weeks following TUR. The incidence of recurrence and progression were 15.3% and 5.10%, respectively. Treatment was well-tolerated and there were minimum side effects.
Chemoprophylaxis with alternating mitomycin-C and BCG therapy in patients with superficial urothelial cancer achieves good results. It is well-tolerated and few side effects were observed.
